iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of posters on its novel A2A receptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, taking place from November 8-12, 2017 in National Harbor, Maryland.

Title: A novel non-competitive and non-brain penetrant adenosine A2A receptor antagonist designed to reverse adenosine-mediated suppression of anti-tumor immunity
Date & Time: Friday, November 10, 2017
Authors: Houthuys, et al.
Poster Number: 483

 

Title: Anti-tumor efficacy and enhancement of T cell effector functions by EOS084448, an antagonist anti-TIGIT antibody
Date & Time: Saturday, November 11, 2017
Authors: Driessens, et al.
Poster Number: 318

 

“These preclinical results show the therapeutic potential of our best-in-class approach which targets the inhibition of the A2A receptor in high intra-tumoral adenosine concentrations where A2A receptor antagonists commonly fail to perform,” commented Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our TIGIT antagonist monoclonal antibody demonstrates a unique profile in preclinical models, including monotherapy efficacy. These findings promise both the development of new monotherapies as well as combinations with other immunotherapeutic agents such as anti-PD1/PDL1 that could potentially improve efficacy.”

Note

About the A2A Receptor and its Cancer Therapeutic Applications
The adenosine A2A receptor is the main adenosine receptor expressed on immune cells, which promote anti-tumor immune responses, leading to tumor regression when inhibited with an adenosine A2A antagonist. iTeos’ best-in-class adenosine A2A receptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models.

 

About the TIGIT Antibody and its Cancer Therapeutic Applications
TIGIT (T-cell Immunoreceptor With Ig And ITIM Domains) is a co-inhibitory receptor expressed on all T-cell subtypes and NK cells which triggers a negative signal in the cell when bound to, preventing their activation. TIGIT expression in effector and regulatory T-cells is significantly enhanced in the tumor microenvironment of cancer patients, and marks a highly suppressive population in regulatory T-cells. iTeos’ TIGIT antagonist monoclonal antibody (EOS084448) demonstrates strong anti-tumor efficacy and the potential to increase primary T-cell functions in animal models in monotherapy and combination with PD(L)-1. EOS084448 is currently being evaluated for safety and efficacy in preclinical models.

 

About iTeos Therapeutics SA
iTeos is focused on expanding the benefits of immunotherapy for cancer patients by developing a proprietary pipeline targeting A2A, immune checkpoints and non-immunogenic (“cold”) tumors. It has licensed its IDO1 program, currently in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery, translational tumor immunology and early clinical trial design. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. Based in Gosselies, Belgium, iTeos is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information, please visit www.iteostherapeutics.com.

 

 

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?